B. Lum

Statistics

Publications

Citations

1.4K

H-Index

Active since

2005

Affiliations

The Barbara Ann Karmanos Cancer Institute(Current)

B. Lum is an author at The Barbara Ann Karmanos Cancer Institute specializing in clinical pharmacokinetics, pharmacokinetics of anticancer drugs, and pharmacology.

Publications per year

2005–2018

Publications

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

Daniel D. Von Hoff, Patricia LoRusso, Charles M. Rudin et al. · New England Journal of Medicine · 2009 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non–small cell lung cancer

Jianfeng Lü, Steve Eppler, J WOLF et al. · Clinical Pharmacology & Therapeutics · 2006 · 224 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +13

Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma

Roy S. Herbst, David S. Mendelson, Sabine Eckhardt et al. · Journal of Clinical Oncology · 2006 · 33 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +16

Tarceva™ (erlotinib) exposure/effects (EE) analysis from a Phase III study in advanced NSCLC: Effect of smoking on the PK of erlotinib

Marta Hamilton, Julie Wolf, Denni M. Zborowski et al. · 2005 · 17 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +17

A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory

Emilie Schindler, Lena E. Friberg, B. Lum et al. · Pharmaceutical Research · 2018 · 17 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

1–5 of 5